Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

ClinicalTrials.gov ID: NCT06040541

Public ClinicalTrials.gov record NCT06040541. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 2, 2026, 11:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 1/1b, Multicenter, Open-Label, Study of RMC 9805 in Participants With Advanced KRASG 12D-Mutant Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.

Study identification

NCT ID: NCT06040541
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Revolution Medicines, Inc.; Industry
Enrollment: 604 participants

Conditions and interventions

Conditions

Interventions

RMC-9805 Drug
RMC-6236 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 6, 2023
Primary completion: Dec 30, 2026
Completion: Apr 29, 2027
Last update posted: Jun 2, 2026

2023 – 2027

United States locations

U.S. sites: 17
U.S. states: 11
U.S. cities: 15

Facility	City	State	ZIP	Site status
University of California, Davis Comprehensive Cancer Center	Sacramento	California	95817	Recruiting
Smilow Cancer Hospital (Yale University)	New Haven	Connecticut	06511	Recruiting
Florida Cancer Specialists	Sarasota	Florida	34232	Recruiting
Lee Moffitt Cancer Center	Tampa	Florida	33612	Recruiting
Johns Hopkins University	Baltimore	Maryland	21287	Recruiting
Massachusetts General Hospital	Boston	Massachusetts	02114	Recruiting
Dana-Farber Cancer Institute	Boston	Massachusetts	02215	Recruiting
NYU Langone	New York	New York	10016	Recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	10065	Recruiting
Duke Cancer Center	Durham	North Carolina	27710	Recruiting
Carolina BioOncology Institute	Huntersville	North Carolina	28078	Recruiting
The Christ Hospital	Cincinnati	Ohio	45219	Recruiting
Sarah Cannon Research Institute	Nashville	Tennessee	37203	Recruiting
Sarah Cannon Research Institute at Mary Crowley	Dallas	Texas	75230	Recruiting
University of Texas, MD Anderson Cancer Center	Houston	Texas	77030	Recruiting
START	San Antonio	Texas	78229	Recruiting
NEXT Oncology Virginia	Fairfax	Virginia	22031	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06040541, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 2, 2026 · Synced Sep 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06040541 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →